The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...

Lewy body dementia is a progressive neurodegenerative disorder brought on by an excess of the protein alpha-synuclein in the brain. These deposits, known as Lewy bodies, can inhibit the production of ...

While Alzheimer’s disease is the most common type of dementia, there’s another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US. It is ...

(WNDU) - We all know about Alzheimer’s disease, in fact, many of us know someone who has been impacted by it. But there is another form of dementia that affects more than a million Americans. And yet, ...

Q: My husband was just diagnosed with Lewy Body Dementia. Can you help me understand this? A: I am sorry about this recent diagnosis. Lewy Body Dementia (LBD) is a complex and challenging brain ...

The Penguin recently aired its sixth episode. The episode was filled with interesting twists and turns, leaving viewers on the edge of their seats. One of the major revelations made in the episode was ...

Please provide your email address to receive an email when new articles are posted on . According to results from the exploratory phase 2 SHIMMER clinical trial, a small molecule oligomer antagonist ...

People with multimorbidity, defined as two or more long‐term conditions occurring within the same patient at the same time, ...

- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase ...

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of ...